Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in dog and rat models of in vivo reperfused myocardial infarction

Journal of Cardiac Failure

Volumn 10, Issue 1, 2004, Pages 74-82

  Jugdutt, Bodh I ^a   Menon, Vijayan ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin II; infarct size; receptors; remodeling; ventricular function

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIASTOLE; DOG; DRUG EFFECT; DRUG MECHANISM; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEMODYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOGS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIUM; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; TETRAZOLES; TREATMENT OUTCOME; UP-REGULATION; VALINE; VENTRICULAR FUNCTION, LEFT;

EID: 3042771034     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(03)00584-0     Document Type: Article

References (61)

1. Ford W.R., Khan M.I., Jugdutt B.I. Effect of the novel angiotensin II type 1 receptor antagonist L-158, 809 on acute infarct expansion and acute anterior myocardial infarction in the dog. Can J Cardiol. 14:1998;73-80
2. Yoshiyama M., Kim S., Yamagishi H., Omura T., Tant T., Yanagi S., et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J. 128:1994;1-6
3. Yang B.C., Phillips M.I., Ambeuhl P.E.J., Shen L.P., Mehta P., Mehta J.L. Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in isolated rat hearts. Circulation. 96:1997;922-926
4. Schwarz E.R., Montino H., Fleischhauer J., Klues H.G., vom Dahl J., Hanrath P. Angiotensin II receptor antagonist EXP3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart. Cardiovasc Drugs Ther. 11:1997;687-695
5. 2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol. 32:1998;1787-1796
6. 1 receptor antagonist candesartan. Basic Res Cardiol. 94:1999;208-214
7. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U., et al., The LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:2002;1004-1010
8. Pitt B., Segal R., Martinez F.A., Meurers G., Cowley A.J., Thomas I., et al., on behalf of the ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in Elderly Study, ELITE). Lancet. 349:1997;747-752
9. McKelvie R.S., Yusuf S., Pericak D., Avezum A., Burns R.J., Probstfield J., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation. 100:1999;1056-1064
10. Pitt B., Poole-Wilson P.A., Segal R., Martinez F.A., Dickstein K., Camm A.J., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 355:2000;1582-1587
11. Cohn J.N., Tognoni G., Glazer R.D., Spormann D., Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Cardiac Failure. 5:1999;155-160
12. Cohn J.N., Tognoni G., for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 345:2001;1667-1675
13. Dickstein K., Kjekshus J., OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 360:2002;752-760
14. Ryan T.J., Antman E.M., Brooks N.H., Califf R.M., Hillis L.D., Hiratzka L.F., et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. 100:1999;1016-1030
15. Horiuchi M., Akishita M., Dzau V.J. Recent progress in Angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 33:1999;613-621
16. Regitz-Zagrosek V., Auch-Shwelk W., Neuss M., Fleck E. Regulation of angiotensin receptor subtypes in cell cultures, animal models and human diseases. Eur Heart J. 15:1994;92-97
17. Lefroy D.C., Wharton J., Crake T., Knock G.A., Rutherford R.A.D., Susuki T., et al. Regional changes in angiotensin II receptor density after experimental myocardial infarction. J Mol Cell Cardiol. 28:1996;429-440
18. 2 angiotensin receptor gene expression in human heart failure. Circulation. 95:1997;1201-1206
19. εproteins. J Renin-Angiotensin Aldosterone Syst. 1:2000;184-195
20. ε proteins and cGMP. J Cardiovasc Pharmacol Therapeut. 5:2000;301-311
21. Jugdutt B.I., Xu Y., Balghith M., Menon V. Cardioprotective effects of angiotensin II type 1 receptor blockade with candesartan after reperfused myocardial infarction: role of angiotensin II type 2 receptor. J Renin-Angiotensin Aldosterone Syst. 2:2001;S162-S166
22. 1R blockade. Can J Cardiol. 18:2002;1107-1116
23. 2 receptors in endothelial cells and isolated ischemic rat hearts. J Hypertens. 11:1993;S234-S235
24. Liu Y.H., Yang X.P., Sharov V.G., Nass O., Sabbah H.N., Peterson E., Carretero O.A. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin type 2 receptors. J Clin Invest. 99:1997;1926-1935
25. Gohlke P., Pees C., Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 31:1998;349-355
26. 1 receptor blockade after reperfused myocardial infarction. J Renin-Angiotensin Aldosterone Syst. 2:2001;134-140
27. 1 receptor blockade in reperfused myocardial infarction. Dhalla N. Signal transduction and cardiac hypertrophy. 2002;221-236 Kluwer Academic Publishers, Boston
28. Jugdutt B.I. Effect of reperfusion on ventricular mass, topography and function during healing of anterior infarction. Am J Physiol. 272:1997;H1205-H1211
29. Jugdutt B.I., Joljart M.J., Khan M.I. Rate of collagen deposition during healing after myocardial infarction in the rat and dog models: mechanistic insights into ventricular remodeling. Circulation. 94:1996;94-101
30. Matsumura K., Jeremy R.W., Schaper J., Becker L.C. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation. 97:1998;795-804
31. Becker L.C., Jeremy R.W., Schaper J., Schaper W. Ultrastructural assessment of myocardial necrosis occurring during ischemia and 3-h reperfusion in the dog. Am J Physiol. 277:1999;H243-H252
32. Criscione L., de Gasparo M., Buhlmayer P., Whitebread S., Ramjoue H.P., Wood J. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol. 110:1993;761-771
33. Fishbein M.C., Meerbaum S., Rit J., Lando U., Kanmatsuse K., Mercier J.C., et al. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J. 101:1981;593-600
34. Balghith M., Jugdutt B.I. Assessment of diastolic dysfunction after acute myocardial infarction using Doppler Echocardiography. Can J Cardiol. 18:2001;69-77
35. Slama M., Susic D., Varagic J., Ahn J., Frohlich E.D. Echocardiographic measurement of cardiac output in rats. Am J Physiol. 284:2003;H691-H697
36. Mizushige K., Yao L., Noma T., Kiyomoto H., Yu Y., Hosomi N., et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of type II diabetic rat model. Circulation. 101:2000;899-907
37. Ping P., Takano H., Zhang J., Tang X.-L., Qiu Y., Li R.C.X., et al. Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits. A signaling mechanism for both nitric-oxide-induced and ischemia-induced preconditiong. Circ Res. 84:1999;587-604
38. Reimer K.A., Jennings R.B. The 'wavefront phenomenon' of myocardial ischemic cell death II: transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest. 40:1979;633-644
39. Richard V., Murry C.E., Reimer K.A. Healing of myocardial infarcts in dogs. Effects of late reperfusion. Circulation. 92:1995;1891-1901
40. Hochman J.S., Choo H. Limitation of myocardial expansion by reperfusion independent of myocardial salvage. Circulation. 75:1987;299-306
41. Jugdutt B.I., Warnica J.W. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion and complications: effect of timing, dosage and infarct location. Circulation. 78:1988;906-919
42. Jugdutt B.I., Khan M.I., Jugdutt S.J., Blinston G.E. Impact of left ventricular unloading after late reperfusion of canine anterior myocardial infarction on remodeling and function using isosorbide-5-mononitrate. Circulation. 92:1995;926-934
43. Weisman H.F., Bush D.E., Mannisi J.A., Weisfeldt M.L., Healy B. Cellular mechanisms of myocardial infarct expansion. Circulation. 78:1988;186-201
44. Zhao M., Zhang H., Robinson T.F., Factor S.M., Sonnenblick E.H., Eng C. Profound structural alterations of the extracellular collagen matrix in postischemic dysfunctional ("stunned") but viable myocardium. J Am Coll Cardiol. 10:1987;1322-1334
45. Bolli R. Mechanism of myocardial stunning. Circulation. 82:1990;723-738
46. Seyedi N., Xu X.B., Nasjletti A., Hintze T.H. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 26:1995;164-170
47. Kelly R.A., Balligand J.-L., Smith T.W. Nitric oxide and cardiac function. Circ Res. 79:1996;363-380
48. Campbell D.J., Kladis A., Valentijn A.J. Effects of losartan on angiotensin and bradykinin peptides and converting enzyme. J Cardiovasc Pharmacol. 26:1995;233-240
49. Christen Y., Waeber B., Nussberger J., Porchet M., Borland R.M., Lee R.J., et al. Oral administration of DuP753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation. 83:1991;1333-1342
50. Hübner R., Högemann A.M., Sunzel M., Riddell J.G. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilextil in young and elderly human volunteers. J Hum Hypertens. II:(Suppl 2):1997;S19-S25
51. Bartunek J., Weinberg E.O., Tajima M., Rohrbach S., Lorell B.H. Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Circulation. 99:1999;22-25
52. Fryer L.G.D., Holness M.J., Decock J.B.J., Sugden M.C. Cardiac protein kinase C expression in two models of cardiac hypertrophy associated with activated cardiac renin-angiotensin system: effects of experimental hyperthyroidism and genetic hypertension (the mRen-2 rat). J Endocrin. 158:1998;27-33
53. Laursen J.B., Rajagopalan S., Galis Z., Tarpey M., Freeman B.A., Harrisin D.G. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 95:1997;588-593
54. Yasmin W., Strynadka K.D., Schulz R. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res. 33:1997;422-432
55. Youhua Z., Shouchun X. Increased vulnerability of hypertrophied myocardium to ischemia and reperfusion injury. Relation to cardiac renin-angiotensin system. Chin Med J. 108:1995;28-32
56. 2 receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. Am J Physiology (Heart Circ Physiol). 282:2002;H1206-H1215
57. Urata H.B., Healy B., Stewart R.W., Bumpus F.M., Husain A. Angiotensin II-forming pathways in normal and failing hearts. Circ Res. 66:1990;883-890
58. Yamada T., Horiuchi M., Dzau V.J. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A. 93:1996;156-160
59. Fliss H., Gattinger D. Apoptosis in ischemic and reperfusion rat myocardium. Circ Res. 79:1996;949-956
60. Moudgil R., Menon V., Xu Y., Musat-Marcu S., Kumar D., Jugdutt B.I. Postischemic apoptosis and functional recovery after angiotensin II type 1 receptor blockade in working rat hearts. J of Hypertension. 19:2001;1121-1129
61. Kajstura J., Cigola E., Malhotra A., Li P., Cheng W., Meggs L.G., et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Moll Cell Cardiol. 29:1997;859-870